Literature DB >> 1904015

Intravenous nitroglycerin infusion inhibits cyclic blood flow responses caused by periodic platelet thrombus formation in stenosed canine coronary arteries.

J D Folts1, J Stamler, J Loscalzo.   

Abstract

BACKGROUND: Nitroglycerin and other clinically relevant organic nitrate derivatives have been shown to inhibit platelet aggregation in vitro. This antithrombotic effect of nitrates is potentiated by reduced thiol. To determine the potential relevance of this mechanism of action in vivo, we examined the effect of intravenous nitroglycerin infusion on periodic platelet thrombus formation in a canine model of coronary artery stenosis. METHODS AND
RESULTS: We used a canine model of coronary artery stenosis associated with cyclic reductions in coronary blood flow that have been shown to depend on periodic platelet thrombus formation. We quantified the frequency of cycles per 40-minute observation period and monitored the effect of a continuous infusion of intravenous nitroglycerin on the cycle frequency. The administration of 10-15 micrograms/kg/min nitroglycerin reduced cyclic platelet thrombus formation significantly and did so without a significant change in coronary artery blood flow. Pretreatment with the reduced thiol, N-acetylcysteine (100 mg/kg during 30 minutes), led to inhibition of cyclic platelet thrombus formation by intravenous nitroglycerin at doses that alone had no such effect (5 micrograms/kg/min).
CONCLUSION: These data suggest that one mechanism by which intravenous nitroglycerin improves ischemia in acute coronary artery disease syndromes may be by inhibition of platelet thrombus formation and may highlight the potential importance of reduced thiol in this mechanism.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1904015     DOI: 10.1161/01.cir.83.6.2122

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  12 in total

Review 1.  How to standardize vasomotor tone in serial studies based on quantitation of coronary dimensions?

Authors:  S Jost; C W Nolte; M Sturm; J Hausleiter; D Hausmann
Journal:  Int J Card Imaging       Date:  1998-12

2.  Inhibition of platelet aggregation by transdermal glyceryl trinitrate.

Authors:  R Andrews; J A May; J Vickers; S Heptinstall
Journal:  Br Heart J       Date:  1994-12

3.  Redox Pioneer: Professor Joseph Loscalzo.

Authors:  Jane A Leopold
Journal:  Antioxid Redox Signal       Date:  2010-10-01       Impact factor: 8.401

4.  Evaluation of platelet function in aspirin treated patients with CAD.

Authors:  Marlene S Williams; Thomas S Kickler; Dhananjay Vaidya; Ladina S Ng'alla; David E Bush
Journal:  J Thromb Thrombolysis       Date:  2006-06       Impact factor: 2.300

5.  Preservation of platelet responsiveness to nitroglycerine despite development of vascular nitrate tolerance.

Authors:  Andrew S Holmes; Yuliy Y Chirkov; Scott R Willoughby; Susan Poropat; Jeremy Pereira; John D Horowitz
Journal:  Br J Clin Pharmacol       Date:  2005-10       Impact factor: 4.335

Review 6.  The Role of Nitroglycerin and Other Nitrogen Oxides in Cardiovascular Therapeutics.

Authors:  Sanjay Divakaran; Joseph Loscalzo
Journal:  J Am Coll Cardiol       Date:  2017-11-07       Impact factor: 24.094

Review 7.  Daily life cardiac ischaemia. Should it be treated?

Authors:  B D Bertolet; C J Pepine
Journal:  Drugs       Date:  1995-02       Impact factor: 9.546

Review 8.  Nitrates for unstable angina.

Authors:  U Thadani; L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1994-10       Impact factor: 3.727

Review 9.  Nitric oxide insufficiency and atherothrombosis.

Authors:  Barbara Voetsch; Richard C Jin; Joseph Loscalzo
Journal:  Histochem Cell Biol       Date:  2004-08-26       Impact factor: 4.304

10.  Progression of heart failure is attenuated by antioxidant therapy with N-acetylcysteine in myocardial infarcted female rats.

Authors:  César R M Costa; Fernando A C Seara; Milena S Peixoto; Isalira P Ramos; Raiana A Q Barbosa; Adriana B Carvalho; Rodrigo S Fortunato; Anderson L B Silveira; Emerson L Olivares
Journal:  Mol Biol Rep       Date:  2020-10-13       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.